Last Updated : July 27, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Venclexta | Venetoclax | Withdrawn | ||||
| Cyramza | Ramucirumab | Cancelled | ||||
| Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
| Avastin | Bevacizumab | Withdrawn | ||||
| TBD | Cabozantinib | Withdrawn | ||||
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
| Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn | |||
| Erbitux | Cetuximab | Cancelled |
Last Updated : July 27, 2024